Last €1.14 EUR
Change Today -0.014 / -1.22%
Volume 0.0
TEHN On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 1:35 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

peregrine pharmaceuticals (TEHN) Snapshot

Open
€1.17
Previous Close
€1.15
Day High
€1.17
Day Low
€1.13
52 Week High
03/6/14 - €2.25
52 Week Low
12/23/13 - €0.91
Market Cap
206.7M
Average Volume 10 Days
931.0
EPS TTM
--
Shares Outstanding
182.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PEREGRINE PHARMACEUTICALS (TEHN)

peregrine pharmaceuticals (TEHN) Related Businessweek News

No Related Businessweek News Found

peregrine pharmaceuticals (TEHN) Details

Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States. Its lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small cell lung cancer along with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also evaluating its lead molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of various solid tumor types. In addition, it provides contract manufacturing services ranging from cell line development to commercial current good manufacturing practice biomanufacturing to third-party clients. The company has various license agreements with the University of Texas Southwestern Medical Center at Dallas; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; Lonza Biologics; Affitech A/S; and Merck KGaA. Peregrine Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Tustin, California.

180 Employees
Last Reported Date: 07/14/14
Founded in 1981

peregrine pharmaceuticals (TEHN) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $557.7K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $423.6K
Vice President, General Counsel and Corporate...
Total Annual Compensation: $393.8K
Vice President of Intellectual Property
Total Annual Compensation: $364.7K
Vice President of Clinical & Regulatory Affai...
Total Annual Compensation: $338.0K
Compensation as of Fiscal Year 2014.

peregrine pharmaceuticals (TEHN) Key Developments

Peregrine Pharmaceuticals, Inc. Announces Preclinical Data from Recently Conducted Single Agent Studies at 2014 San Antonio Breast Cancer Symposium in San Antonio, Texas

Peregrine Pharmaceuticals, Inc. announced preclinical data from recently conducted single agent studies at the 2014 San Antonio Breast Cancer Symposium in San Antonio, Texas being held December 9-13, 2014. In a poster titled ‘Antibody-mediated Blockade of Phosphatidylserine Enhances the Anti-tumor Activity of Immune Checkpoint Inhibitor a-PD-1 by Affecting Myeloid Derived Suppressor Cells (MDSC) and Lymphocyte Populations in a Breast Tumor Microenvironment,’ newly published data show that ch1N11, the preclinical equivalent to bavituximab, as a single agent, demonstrated statistically significant (p=0.025) tumor growth inhibition in mice bearing EMT-6 breast tumors when compared to a control antibody. In addition, researchers using fluorescence-activated cell sorting (FACS) found that the single agent treatment of tumor bearing mice with ch1N11 yielded statistically significant increases in the percentage of CD4 (p=0.016) and CD8 (p=0.018) tumor infiltrating lymphocytes and decreases tumor MDSC/CD4 (p=0.026) and MDSC/CD8 (p=0.014) ratios, all key indicators of stimulating immune activation.

Peregrine Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended October 31, 2014; Provides Contract Manufacturing Revenue Guidance for the Fiscal Year 2015

Peregrine Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter ad six months ended October 31, 2014. For the quarter, the company reported total revenues of $6,300,000 against $7,354,000 a year ago. Loss from operations was $12,137,000 against $7,814,000 a year ago. Net loss was $12,100,000 against $7,790,000 a year ago. Net loss attributable to common stockholders was $13,131,000 against $7,790,000 a year ago. Basic and diluted loss per common share was $0.07 against $0.05 a year ago. For the six months, the company reported total revenues of $11,796,000 against $12,042,000 a year ago. Loss from operations was $25,308,000 against $15,434,000 a year ago. Net loss was $25,229,000 against $15,390,000 a year ago. Net loss attributable to common stockholders was $27,031,000 against $15,390,000 a year ago. Basic and diluted loss per common share was $0.15 against $0.10 a year ago. For the fiscal year 2015, the company expects contract manufacturing revenue to be between $19 and $23 million.

Peregrine Pharmaceuticals, Inc. Declares Quarterly Cash Dividend on 10.50% Series E Convertible Preferred Stock, Payable on January 2, 2015

Peregrine Pharmaceuticals, Inc. announced that its Board of Directors has declared a quarterly cash dividend payment on the company's 10.50% Series E Convertible Preferred Stock. The quarterly dividend on the Series E Preferred Stock is payable on January 2, 2015 to holders of record at the close of business on December 19, 2014. The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share stated liquidation preference, accruing from October 1, 2014 through December 31, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEHN:GR €1.14 EUR -0.014

TEHN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Argos Therapeutics Inc $9.52 USD +0.28
Dynavax Technologies Corp $15.34 USD -0.18
Genocea Biosciences Inc $7.53 USD -0.02
Inovio Pharmaceuticals Inc $9.48 USD +0.47
Vical Inc $1.07 USD 0.00
View Industry Companies
 

Industry Analysis

TEHN

Industry Average

Valuation TEHN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.5x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PEREGRINE PHARMACEUTICALS, please visit www.peregrineinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.